ALKS (Alkermes PLC) Rega marang bathi mangsa ngarep

Logo grafis Alkermes plc (ALKS)

Alkermes plc (ALKS) maintains its leadership in psychiatric treatment through complex injectable drug formulations. Operations are based on clinical trial outcomes and patent expiration dates. The company's forward P/E ratio on this GURU.Markets chart clearly visualizes the trend, where the value 83.40 captures this metric. Market capitalization growth depends on Lybalvi sales, royalties, and R&D efficiency in oncology.

Kapitalisasi marang proyeksi bathi: Alkermes PLC (ALKS) kanggo 04.07.2022 - 12.11.2026

Rincian metrik lan analitis perusahaan Alkermes Corp (ALKS)

- rega saiki lan proyeksi nilai saham:
Kutipan saham Alkermes|ALKS - Konsensus nilai wajar
- indikator valuasi pasar bisnis:
Nilai pasar Alkermes PLC|ALKS - Nilai Wutuh Bisnis
- data ekuitas miturut neraca:
Aset Bersih saben Siji Saham Alkermes|ALKS - Pambiji Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih alkermes.com|ALKS - Aset Perusahaan
- indikator total utang lan likuiditas perusahaan:
Total Utang marang Modal Alkermes plc|ALKS - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Alkermes plc|ALKS - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Alkermes PLC|ALKS - Utang jangka dawa|Utang jangka cendhak perusahaan Alkermes|Likuiditas cepet alkermes.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
ALKS - Bathi resik perusahaan|Bathi sing dikarepake Alkermes plc|ALKS - Pangali P/E|Pangali Forward P/E Alkermes Inc.|ALKS - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Alkermes PLC|ALKS - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Alkermes|ALKS - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan alkermes.com|ALKS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Alkermes plc
Pambiji fundamental:ALKS Alkermes
Produk merek Alkermes Corp

Forward P/E determines the market value of a business relative to expected net income, allowing an investor to assess the asset's degree of overheating and the margin of safety under shifting development scenarios. For Alkermes plc (ALKS), with its inelastic demand for schizophrenia medications, this calculation reflects a premium for unique drug delivery systems, which is clearly captured by the company's projected P/E multiple.

Pesaing Alkermes plc (ALKS)

Prakiraan rega marang bathi AVDL (Avadel Pharmaceuticals plc)|ATAI (atai Life Sciences NV) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep GH Research Corp GHRS|MNMD (Mind Medicine Corp) - Rasio rega marang bathi sing dikarepake|CMPS - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi lbpharma.us LBRX|DRUG (Bright Minds Biosciences Inc.) - Prakiraan rega marang bathi|Rasio prakiraan rega marang bathi Vanda Pharma (VNDA)|CYBN (Cybin Inc) - Pangali Forward P/E|Prakiraan rega marang bathi Alto Neuroscience Corp (ANRO)|Pangali Forward P/E NRXP|CING (cingulate.com) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Silo Pharma, Inc. SILO|China Pharma Holdings Inc. (CPHI) - Rasio prakiraan rega marang bathi|Clearmind Medicine - Pangali Forward P/E|PBM - Pangali Forward P/E|SciSparc Ltd (SPRC) - Rega marang bathi mangsa ngarep|SEEL (seelostherapeutics.com) - Rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Virpax Pharmaceuticals Inc.|Pangali Forward P/E Karuna Therapeutics Inc